ArticleMolecular biology reports2025
Targeting the IL-6R/STAT3/PD-L1 axis: lobaric acid and Tocilizumab as a promising combination immunotherapy in ovarian cancer.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundOvarian cancer is the most deadly gynecological malignancy, largely due to difficulties in early detection, therapeutic resistance and toxicity. The aim of this study was to evaluate the potential therapeutic effects of the small-molecule drug candidate lobaric acid (LA) as monotherapy and in combination with tocilizumab (TCZ) and atezolizumab (ATE) in ovarian cancer. METHODS AND
resultsIn this study, the anti-proliferative and immunotherapeutic effects of LA, TCZ, and ATE in different ovarian cancer cell lines were determined. In addition, the intracellular signalling effects of LA and its combination with TCZ were extensively investigated by silencing the STAT3 pathway and the results were confirmed. This study demonstrated for the first time that the combination of LA and TCZ exerts a significant immunotherapeutic effect on ovarian cancer cells. LA treatment, either as monotherapy or in combination with TCZ, was found to have therapeutic potential for ovarian cancer without cytotoxic effects on healthy cells.
conclusionsThese findings emphasise that LA is a promising candidate for the treatment of ovarian cancer and indicate its potential for inclusion in advanced treatment protocols.
Indexed as
Identifiers
41065878What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.